
Septerna Inc (SEPN) Stock Forecast & Price Target
Septerna Inc (SEPN) Analyst Ratings
Bulls say
Septerna Inc. possesses a modest enterprise value of approximately $430 million, suggesting a significant long-term upside potential of 8-10 times the current share price, particularly if its partnership with Novoproves proves successful. The company's management anticipates enhanced efficiency in executing Phase 1 trials for SEP-786 based on previous experience, which could accelerate project timelines. Additionally, if SEP-631 demonstrates similar efficacy to Xolair, which achieved nearly $3.9 billion in total sales in 2023, it has the potential to reach blockbuster status, further bolstering Septerna's financial standing in the market.
Bears say
The financial outlook for Septerna Inc. is negatively impacted by multiple risks inherent in its clinical development process, including potential delays in advancing key candidates such as SEP-631, as well as setbacks during clinical trials. Additional concerns stem from the partnership with Novo Nordisk, which may introduce uncertainties, especially in securing approvals for leading product candidates and achieving anticipated market penetration rates. Furthermore, the implications of possible long-term dilution pose additional financial risks, further exacerbated by a recently highlighted valuation gap in the obesity sector.
This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.
Septerna Inc (SEPN) Analyst Forecast & Price Prediction
Start investing in Septerna Inc (SEPN)
Order type
Buy in
Order amount
Est. shares
0 shares